Florbetapir (18F) (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Florbetapir (18F)" in English language version.

refsWebsite

Global rank English rank

6nih.gov

4^th place

5nytimes.com

7^th place

1ama-assn.org

3,257^th place

3,398^th place

1europa.eu

68^th place

117^th place

1fda.gov

447^th place

338^th place

1web.archive.org

1^st place

1doi.org

2^nd place

1diagnosticimaging.com

low place

1medicalnewstoday.com

3,011^th place

2,709^th place

1newsbank.com

414^th place

253^rd place

1ecnext.com

8,927^th place

5,702^nd place

1forbes.com

54^th place

48^th place

ama-assn.org

searchusan.ama-assn.org

"Statement on a Nonproprietary Name Adopted by the USAN Council - Florbetapir F 18" (PDF). United States Adopted Name (USAN) Drug Finder. American Medical Association. Retrieved 18 March 2022.

diagnosticimaging.com

Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. (June 2010). "In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)". Journal of Nuclear Medicine. 51 (6): 913–920. doi:10.2967/jnumed.109.069088. PMC 3101877. PMID 20501908.
- Lay summary in: "FDA Approves PET Imaging Agent for Alzheimer's Evaluation". Diagnostic Imaging. 9 April 2012.

doi.org

Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. (June 2010). "In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)". Journal of Nuclear Medicine. 51 (6): 913–920. doi:10.2967/jnumed.109.069088. PMC 3101877. PMID 20501908.
- Lay summary in: "FDA Approves PET Imaging Agent for Alzheimer's Evaluation". Diagnostic Imaging. 9 April 2012.

ecnext.com

goliath.ecnext.com

"Avid Radiopharmaceuticals Selected to Receive Seed Funding from BioAdvance; Funds to Be Used to Develop Molecular Imaging Tools for Alzheimer's Disease". Business Wire. 5 January 2005. Retrieved 23 June 2010.

europa.eu

ema.europa.eu

"Amyvid EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 12 January 2021.

fda.gov

accessdata.fda.gov

"Drug Approval Package: Amyvid (florbetapir F 18) NDA 202008". U.S. Food and Drug Administration. 3 May 2012. Retrieved 12 October 2021.

forbes.com

"Lilly Snags Avid Radiopharma". Forbes. 8 November 2010. Retrieved 8 November 2010.

medicalnewstoday.com

"Avid Radiopharmaceuticals Initiates First Phase II Trial Of Novel Compound For Imaging Alzheimer's Disease". Medical News Today. 11 June 2008. Retrieved 23 June 2010.

newsbank.com

nl.newsbank.com

"Phila. start-up developing a way to test for Alzheimer's, Avid Radiopharmaceuticals has raised $26 million in new venture financing. Seeking a test for Alzheimer's". The Philadelphia Inquirer. 9 May 2007. Retrieved 23 June 2010.

nih.gov

pubmed.ncbi.nlm.nih.gov

Carpenter AP, Pontecorvo MJ, Hefti FF, Skovronsky DM (August 2009). "The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience". The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 53 (4): 387–393. PMID 19834448.
Leung K (8 April 2010). "(E)-4-(2-(6-(2-(2-(2-(¹⁸F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine [[¹⁸F]AV-45]". Molecular Imaging and Contrast Agent Database. PMID 20641982. Retrieved 24 June 2010.
Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. (June 2010). "In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)". Journal of Nuclear Medicine. 51 (6): 913–920. doi:10.2967/jnumed.109.069088. PMC 3101877. PMID 20501908.
- Lay summary in: "FDA Approves PET Imaging Agent for Alzheimer's Evaluation". Diagnostic Imaging. 9 April 2012.
ncbi.nlm.nih.gov
- Leung K (8 April 2010). "(E)-4-(2-(6-(2-(2-(2-(¹⁸F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine [[¹⁸F]AV-45]". Molecular Imaging and Contrast Agent Database. PMID 20641982. Retrieved 24 June 2010.
- Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. (June 2010). "In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)". Journal of Nuclear Medicine. 51 (6): 913–920. doi:10.2967/jnumed.109.069088. PMC 3101877. PMID 20501908.
  - Lay summary in: "FDA Approves PET Imaging Agent for Alzheimer's Evaluation". Diagnostic Imaging. 9 April 2012.
  dailymed.nlm.nih.gov
  - "Amyvid- florbetapir f 18 injection, solution". DailyMed. Retrieved 12 January 2021.

nytimes.com

Kolata G (23 June 2010). "Promise Seen for Detection of Alzheimer's". The New York Times. Archived from the original on 28 June 2010. Retrieved 23 June 2010.
Kolata G (23 June 2010). "Promise Seen for Detection of Alzheimer's". The New York Times. Retrieved 23 June 2010.
Kolata G (12 July 2010). "New Scan May Spot Alzheimer's". The New York Times. Retrieved 14 July 2010.
Kolata G (18 January 2011). "Two Tests Could Aid in Risk Assessment and Early Diagnosis of Alzheimer's". The New York Times. Retrieved 19 January 2011.
Kolata G (30 January 2011). "F.D.A. Sees Promise in Alzheimer's Imaging Drug". The New York Times. Retrieved 20 January 2011.

web.archive.org

Kolata G (23 June 2010). "Promise Seen for Detection of Alzheimer's". The New York Times. Archived from the original on 28 June 2010. Retrieved 23 June 2010.